Geneva, May 4 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123039) titled 'Clinical study on the efficacy and safety of Huairu Granules combined with chemotherapy and immunotherapy in the conversion treatment of HER2-negative unresectable advanced gastric cancer' on April 21.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Sichuan Cancer Hospital
Condition:
There is a single initial non-resectable factor - HER2 negative advanced gastric cancer
Intervention:
Trial Group:1. Huaier Granules: 1 sachet (20g) each time, 3 times daily, taken orally continuously until disease progression or surgery
2. Chemotherapy (CAPOX regimen): Capecitabine 1000 mg/m^2, orally...